R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
Child, Adult, Older Adult
Sexes Eligible for Study:
Key Inclusion Criteria:
Males or females in an Ebola endemic region with documented positive polymerase chain reaction (PCR) for Ebola virus infection who are symptomatic
Ability to provide informed consent personally or by a legal representative if the patient is unable to do so, based on local laws and regulations
REGN-EB3 can be administered to pregnant women infected with Zaire ebolavirus, as defined in the protocol
Children of any age will be eligible for enrollment, as defined in the protocol
Neonates born to an infected mother who has not yet cleared the Ebola virus are eligible for enrollment, as defined in the protocol
Key Exclusion Criteria:
Negative EBOV diagnostic test result
A patient who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol
Any serious medical condition that, in the opinion of the site investigator, would place the patient at an unreasonable increased risk through participation in this study, including any past or concurrent conditions
Eligible for an ongoing randomized clinical trial with REGN-EB3
NOTE: Other protocol defined inclusion / exclusion criteria apply